Pfizer Ends CytomX "Probody" Cancer Collaboration

Pfizer has terminated its five-year-old partnership with CytomX Therapeutics to use its Probody™ drug-development platform to develop and commercialize several antibody–drug conjugates (ADCs) for cancer, CytomX has acknowledged.That partnership was originally envisioned to pay CytomX up to $635 million-plus, including milestone payments and royalties.In announcing full-year 2017 financial results yesterday, CytomX said Pfizer notified the company on Tuesday of its intent to end the c